# Effect of Pioglitazone on T2DM Patients With COVID-19

> **NCT04604223** · PHASE4 · UNKNOWN · sponsor: **Dasman Diabetes Institute** · enrollment: 1506 (estimated)

## Conditions studied

- Covid19
- Type 2 Diabetes

## Interventions

- **DRUG:** Pioglitazone 45 mg

## Key facts

- **NCT ID:** NCT04604223
- **Lead sponsor:** Dasman Diabetes Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-18
- **Primary completion:** 2021-06-29
- **Final completion:** 2021-06-29
- **Target enrollment:** 1506 (ESTIMATED)
- **Last updated:** 2021-03-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04604223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04604223, "Effect of Pioglitazone on T2DM Patients With COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04604223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*